Biomerica Stock Analysis

BMRA -  USA Stock  

USD 3.89  0.04  1.04%

The big decline in price over the last few months for Biomerica could raise concerns from investors as the firm it trading at a share price of 3.89 on 21,653 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Biomerica or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.4. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Biomerica partners.
Continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Biomerica stock analysis report makes it easy to digest most publicly released information about Biomerica and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biomerica stock analysis module also helps to analyze the Biomerica price relationship with some important fundamental indicators such as market cap and management efficiency.

Biomerica Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The book value of Biomerica was currently reported as 0.86. The company recorded a loss per share of 0.47. Biomerica had not issued any dividends in recent years. The entity had 1:2 split on the 7th of April 2016. Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection andor treatment of medical conditions and diseases worldwide. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California. Biomerica operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. For more info on Biomerica please contact Zackary Irani at 949 645 2111 or go to http://www.biomerica.com.

Biomerica Quarterly Cost of Revenue

3.67 MillionShare

Biomerica Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biomerica's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biomerica or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biomerica generates negative expected return over the last 90 days
Biomerica has high historical volatility and very poor performance
Biomerica is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 8.87 M. Net Loss for the year was (5.46 M) with profit before overhead, payroll, taxes, and interest of 1.78 M.
Biomerica currently holds about 5.27 M in cash with (7.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.43.
Biomerica has a poor financial position based on the latest SEC disclosures
Roughly 17.0% of the company shares are held by company insiders
Latest headline from www.equities.com: Biomerica Inc. falls -0.9760 percent for June 15 - Equities.com

Biomerica Upcoming and Recent Events

Earnings reports are used by Biomerica to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomerica previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of September 2021
Next Earnings Report21st of October 2021
Next Fiscal Quarter End31st of May 2021
Next Fiscal Year End7th of September 2021
Last Quarter Report28th of February 2021
Last Earning Announcement31st of May 2020

Biomerica Largest EPS Surprises

Earnings surprises can significantly impact Biomerica's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-10-15
2019-08-31-0.06-0.050.0116 
2019-01-14
2018-11-30-0.06-0.050.0116 
2018-10-15
2018-08-31-0.06-0.050.0116 
View All Earnings Estimates

Biomerica SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biomerica prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biomerica investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biomerica specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of February 2021
Unclassified Corporate Event
View
22nd of January 2021
Financial Statements and Exhibits. Other Events
View
20th of January 2021
Unclassified Corporate Event
View
13th of January 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
11th of December 2020
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
30th of November 2020
Unclassified Corporate Event
View
1st of September 2020
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Biomerica Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biomerica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomerica backward and forwards among themselves. Biomerica's institutional investor refers to the entity that pools money to purchase Biomerica's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wellington Management Group LlpCommon Shares973.7 K5.3 M
Granahan Investment Management IncCommon Shares830.1 K4.5 M
Vanguard Group IncCommon Shares600.6 K3.3 M
Russell Investments Group LtdCommon Shares285.3 K1.6 M
Millrace Asset Group IncCommon Shares247.7 K1.4 M
Blackrock IncCommon Shares220.4 K1.2 M
Marshall Wace LlpCommon Shares165.2 K902 K
Susquehanna International Group LlpCall Options37.7 K206 K
Susquehanna International Group LlpPut Options36 K197 K
Note, although Biomerica's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biomerica Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 47.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biomerica's market, we take the total number of its shares issued and multiply it by Biomerica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biomerica Profitablity

Biomerica's profitability indicators refer to fundamental financial ratios that showcase Biomerica's ability to generate income relative to its revenue or operating costs. If, let's say, Biomerica is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biomerica's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biomerica's profitability requires more research than a typical breakdown of Biomerica's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (61.56) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (62.05) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.62.
Last ReportedProjected for 2021
Return on Average Assets(0.21) (0.23) 
Return on Average Equity(0.32) (0.35) 
Return on Invested Capital(0.32) (0.35) 
Return on Sales(0.31) (0.32) 

Management Efficiency

The entity has return on total asset (ROA) of (31.91) % which means that it has lost $31.91 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (71.47) %, meaning that it created substantial loss on money invested by shareholders. Biomerica management efficiency ratios could be used to measure how well biomerica manages its routine affairs as well as how well it operates its assets and liabilities. As of June 17, 2021, Return on Average Assets is expected to decline to -0.23. In addition to that, Return on Average Equity is expected to decline to -0.35. Biomerica Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 19.85 Million. The current year Current Assets is expected to grow to about 18.3 M, whereas Return on Average Assets are forecasted to decline to (0.23) .
Last ReportedProjected for 2021
Book Value per Share 1.61  1.27 
Enterprise Value over EBIT(27.90) (30.10) 
Enterprise Value over EBITDA(33.70) (36.36) 
Price to Book Value 4.63  4.91 
Tangible Assets Book Value per Share 1.93  2.08 
Enterprise Value83.2 M89.8 M
Tangible Asset Value19.7 M21.2 M

Technical Drivers

As of the 17th of June 2021, Biomerica shows the risk adjusted performance of (0.07), and Mean Deviation of 3.36. Biomerica technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Biomerica, which can be compared to its rivals. Please confirm Biomerica maximum drawdown, and the relationship between the information ratio and downside variance to decide if Biomerica is priced correctly, providing market reflects its regular price of 3.89 per share. Given that Biomerica has jensen alpha of (0.52), we suggest you to validate Biomerica's prevailing market performance to make sure the company can sustain itself at a future point.

Biomerica Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Biomerica more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Biomerica Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomerica insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomerica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomerica insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biomerica Predictive Daily Indicators

Biomerica intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biomerica stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biomerica Forecast Models

Biomerica time-series forecasting models is one of many Biomerica's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biomerica's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Biomerica Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biomerica stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biomerica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Biomerica. By using and applying Biomerica Stock analysis, traders can create a robust methodology for identifying Biomerica entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(0.26) (0.27) 
Gross Margin 0.24  0.26 
Profit Margin(0.31) (0.32) 
Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection andor treatment of medical conditions and diseases worldwide. The companys diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patients body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians offices and over-the-counter drugstores, and hospitalclinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patients diet can alleviate the patients IBS symptoms Helicobacter pylori products and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Current Biomerica Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biomerica analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biomerica analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.83Buy3Odds
Biomerica current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biomerica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biomerica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biomerica, talking to its executives and customers, or listening to Biomerica conference calls.
Biomerica Analyst Advice Details

Biomerica Stock Analysis Indicators

Biomerica stock analysis indicators help investors evaluate how Biomerica stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biomerica shares will generate the highest return on investment. By understating and applying Biomerica stock analysis, traders can identify Biomerica position entry and exit signals to maximize returns.
Quick Ratio5.29
Fifty Two Week Low3.3000
Revenue Growth208.30%
Shares Short Prior Month1.03M
Average Daily Volume Last 10 Day540.16k
Average Daily Volume In Three Month305.98k
Shares Percent Shares Out8.30%
Gross Margins13.97%
Short Percent Of Float10.04%
Forward Price Earnings19.25
Float Shares10.18M
Fifty Two Week High12.7500
Enterprise Value To Ebitda-10.06
Fifty Day Average3.9768
Two Hundred Day Average5.5330
Enterprise Value To Revenue6.09
Continue to Trending Equities. Note that the Biomerica information on this page should be used as a complementary analysis to other Biomerica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Biomerica Stock analysis

When running Biomerica stock analysis, check to measure Biomerica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomerica is operating at the current time. Most of Biomerica's stock examination focuses on studying past and present price action to predict the probability of Biomerica's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biomerica's price. Additionally, you may evaluate how the addition of Biomerica to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica stock's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Biomerica value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.